Nasopharyngeal Carcinoma
📧 Sign up to get email alerts when something new happens for Nasopharyngeal Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of Scipibaimab and tislelizumab for first-line treatment-failed recurrent/metastatic nas…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma [Phase 2]
This entry updates a Phase 2 clinical trial investigating the optimal timing of immunotherapy administered during neoadjuvant chemotherapy f…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC [Phase 2]
Phase 2 trial evaluating a PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation for locally advanced recur…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma [Phase 3]
The document reports a Phase 3 clinical trial evaluating Anlotinib in combination with immunotherapy and chemoradiotherapy for high-risk nas…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC [Phase 1]
Phase 1 study evaluating TGF-beta resistant cytotoxic T-lymphocytes for Epstein-Barr virus–positive nasopharyngeal carcinoma. The trial is c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
This clinical trial update notes an ongoing study evaluating intensity-modulated radiotherapy (IMRT) alone for stage I nasopharyngeal carcin…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma [Phase 2]
A Phase 2 clinical trial testing consolidation nivolumab after concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]
Phase 2 clinical trial evaluating a combination of Anlotinib, Penpulimab, and Capecitabine in recurrent/metastatic nasopharyngeal carcinoma.…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial [Phase 2]
This is a Phase IIa, single-arm clinical trial evaluating a triple combination of iparomlimab, tuvonralimab, and nimotuzumab for recurrent o…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors [Phase 2]
Phase 2 clinical trial update for BL-B01D1 in combination with a PD-1 monoclonal antibody in locally advanced or metastatic non-small cell l…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 3]
Phase 3 trial assessing MRG003 in combination with Pucotenlimab versus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma; cu…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma [Phase 2]
Phase 2 clinical trial evaluating SBRT in combination with a PD-1 inhibitor and chemotherapy for oligometastatic nasopharyngeal carcinoma; t…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial [Phase 3]
A Phase III trial is evaluating proton versus photon IMRT for locally advanced nasopharyngeal carcinoma. The study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy [Phase 3]
This Phase 3 clinical trial compares reduced-dose versus conventional-dose intensity-modulated radiation therapy in locally advanced nasopha…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC [Phase 2]
Phase 2 clinical trial evaluating MRG003 induction followed by capecitabine maintenance with a PD-1 inhibitor in locally recurrent nasophary…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma [Phase 3]
A Phase 3 trial is comparing 40.2 Gy versus 49.2 Gy radiotherapy in chemosensitive stage II nasopharyngeal carcinoma with low-risk target vo…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid [Phase 3]
Phase 3 clinical trial evaluating Houyanqing Oral Liquid for prevention and treatment of radiation-induced oral mucositis in nasopharyngeal …
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
A prospective study sponsored by Jiangsu Cancer Institute & Hospital is assessing molecular biomarkers and spatial transcriptomics in nasoph…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC [Phase 3]
Phase 3 clinical trial update for individualized neck and cervical irradiation prophylaxis in nasopharyngeal carcinoma. The study is sponsor…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II) [Phase 2]
Phase 2 single-arm trial evaluating induction high-low dose radiotherapy plus anti-PD-1 therapy followed by definitive radiotherapy for recu…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 2]
Phase 2 trial evaluating neoadjuvant therapy with a PD-1 inhibitor plus gemcitabine and cisplatin for locoregionally advanced nasopharyngeal…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer [Phase 3]
A Phase 3 non-inferiority trial compares reduced-target IMRT to full-target IMRT after chemotherapy in immunotherapy-treated metastatic naso…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Trop2-targeted immunoPET Imaging of Solid Tumors [Phase 2, Phase 3]
Clinical trial update for Trop2-targeted immunoPET imaging of solid tumors, currently in Phase 2/3 and recruiting.
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma [Phase 3]
A Phase 3 clinical trial investigates risk-adapted omission of Level Va irradiation in nasopharyngeal carcinoma, with the study currently NO…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Pembrolizumab + MRGOO3 as Neoadjuvant in NPC [Phase 2]
A Phase 2 neoadjuvant trial of pembrolizumab in combination with MRGOO3 for locoregionally advanced nasopharyngeal carcinoma is listed as no…